Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy Alterations.
Kaparou M, Rudzki Z, Giles H, Murthy V, Srinath S, Lloyd R, Ahmed MZ, Salhan B, Chauhan S, Kishore B, Lovell R, Horgan C, Paneesha S, Xenou E, Lokare A, Ewing J, Dassanayake H, Nikolousis E, Kanellopoulos A. Kaparou M, et al. Among authors: nikolousis e. Case Rep Hematol. 2021 Jan 21;2021:8843063. doi: 10.1155/2021/8843063. eCollection 2021. Case Rep Hematol. 2021. PMID: 33510919 Free PMC article.
Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant.
Nikolousis E, Robinson S, Nagra S, Brookes C, Kinsella F, Tauro S, Jeffries S, Griffiths M, Mahendra P, Cook M, Paneesha S, Lovell R, Kishore B, Chaganti S, Malladi R, Raghavan M, Moss P, Milligan D, Craddock C. Nikolousis E, et al. Leuk Res. 2013 May;37(5):561-5. doi: 10.1016/j.leukres.2013.01.010. Epub 2013 Feb 5. Leuk Res. 2013. PMID: 23395505 Clinical Trial.
Graft-versus-leukaemia effect post fludarabine, melphalan and alemtuzumab reduced intensity allogeneic stem cell transplantat in HIV-infected patient with acute myeloid leukaemia.
Kanellopoulos A, Kaparou M, Xenou E, Paneesha S, Kishore B, Lovell R, Holder K, Suhr J, Baker L, Ryan L, Nikolousis E. Kanellopoulos A, et al. Among authors: nikolousis e. Bone Marrow Transplant. 2018 Dec;53(12):1518-1521. doi: 10.1038/s41409-018-0297-z. Epub 2018 Aug 16. Bone Marrow Transplant. 2018. PMID: 30116019
A unique case of durable complete remission after salvage with azacitidine and DLI for high risk flt-3 positive acute myeloid leukemia, following relapse 18 months post allogeneic stem cell transplant.
Horgan C, Kanellopoulos A, Paneesha S, Kishore B, Lovell R, Nikolousis E. Horgan C, et al. Among authors: nikolousis e. Hematol Rep. 2019 Feb 25;11(1):7800. doi: 10.4081/hr.2019.7800. eCollection 2019 Feb 19. Hematol Rep. 2019. PMID: 30915202 Free PMC article.
Reduced intensity alemtuzumab-containing allogeneic stem cell transplantation for relapsed/refractory low grade lymphoma: reflections on a single center experience.
Horgan C, Elmoamly S, McIlroy G, Davies D, Kaparou M, Giles H, Xenou E, Kishore B, Lovell R, Nikolousis E, Shankara P, Kanellopoulos A. Horgan C, et al. Among authors: nikolousis e. Leuk Lymphoma. 2019 Dec;60(12):3075-3077. doi: 10.1080/10428194.2019.1607323. Epub 2019 May 13. Leuk Lymphoma. 2019. PMID: 31079514 No abstract available.
Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation.
McIlroy G, Nikolousis E, Abou-Zeid N, Shankara P, Kishore B, Kaparou M, Lovell R, Elmoamly S, Davies D, Horgan C, Shenouda A, Kanellopoulos A. McIlroy G, et al. Among authors: nikolousis e. Leuk Lymphoma. 2020 Jan;61(1):202-205. doi: 10.1080/10428194.2019.1650177. Epub 2019 Aug 11. Leuk Lymphoma. 2020. PMID: 31402762 No abstract available.
Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial.
Stanworth SJ, Killick S, McQuilten ZK, Karakantza M, Weinkove R, Smethurst H, Pankhurst LA, Hodge RL, Hopkins V, Thomas HL, Deary AJ, Callum J, Lin Y, Wood EM, Buckstein R, Bowen D; REDDS Investigators. Stanworth SJ, et al. Br J Haematol. 2020 Apr;189(2):279-290. doi: 10.1111/bjh.16347. Epub 2020 Jan 20. Br J Haematol. 2020. PMID: 31960409 Free article. Clinical Trial.
40 results